Inflammatory bowel disease course in liver transplant versus non-liver transplant patients for primary sclerosing cholangitis: LIVIBD, an IG-IBD study

Ribaldone, Davide Giuseppe; Imperatore, Nicola; Grazie, Marco Le; Furfaro, Federica; Balestrieri, Paola; Blasio, Federico De; Fagoonee, Sharmila; Mosso, Elena; Boano, Valentina; Reggio, Dario; Sarli, Ennio; Castiglione, Fabiana; Milla, Mónica; Vecchi, Maurizio; Saracco, Giorgio Maria; Salizzoni, Mauro; Romagnoli, Renato; Fiorino, Gionata; Astegiano, Marco

doi:10.1016/j.dld.2020.09.011

Cited by 6 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 The relationship between immunosuppressants leading to LD is also recognized in the transplant literature, where chronic immunosuppression can lead to the development of post-transplant lymphoproliferative disease [PTLD]. 6,7 Primary intestinal lymphoma [PIL], also known as primary intestinal lymphoproliferative disease, accounts for only 1-4% of all gastrointestinal malignancies. There are three case series and a few additional case reports in the literature of PIL associated with IBD.…”

Section: Introductionmentioning

confidence: 99%

Diagnosis and Outcome of Extranodal Primary Intestinal Lymphoma in Inflammatory Bowel Disease: An ECCO CONFER Case Series

Phillips

Verstockt

Ribaldone

et al. 2021

Journal of Crohn's and Colitis

Self Cite

View full text Add to dashboard Cite

Background There is a small but measurable increased risk of lymphoma in inflammatory bowel disease (IBD), with a suggestion that primary intestinal lymphoma in IBD is associated with inflamed tissue and immunosuppressant use, mainly thiopurines. Methods This multicentre case series was supported by the European Crohn’s and Colitis Organisation (ECCO) and performed as part of the Collaborative Network of Exceptionally Rare case reports (CONFER) project. Clinical data were recorded in a standardized case report form. Results Fifteen patients with intestinal lymphoma from 8 centres were included [12 males, 11 patients with Crohn’s disease, mean age 47.8 (±16.4 SD, range 26-76) years at lymphoma diagnosis]. Lymphoma type was diffuse large B-cell lymphoma (DLBCL) in 8, Hodgkin’s disease in 2, MALT lymphoma in 3, and single cases of immunoblastic lymphoma and indolent T cell lymphoma. Lymphoma was located within the IBD affected area in 10 patients. At lymphoma diagnosis, 9 patients had a history of azathioprine or anti-TNF use. Lymphoma was diagnosed at a mean time of 10.4 (±7.07, 1-24) years after IBD diagnosis in 11 patients, prior to IBD in 2 and concurrently in 2. Sustained remission over a median follow-up time of 6.5 (1.5-20) years was achieved in 10 patients after treatment; 5 of them had started biologic therapy (including anti-TNFs, vedolizumab and ustekinumab) for active CD subsequent to their PIL treatment. Conclusion In this small case series, two thirds of patients developed lymphoma in the IBD-affected area, and almost two thirds had a history of thiopurine or anti-TNF use. Biologics were restarted without recurrence of lymphoma in half of the remitters.

show abstract

Section: Introductionmentioning

confidence: 99%

Diagnosis and Outcome of Extranodal Primary Intestinal Lymphoma in Inflammatory Bowel Disease: An ECCO CONFER Case Series

Phillips

Verstockt

Ribaldone

et al. 2021

Journal of Crohn's and Colitis

Self Cite

View full text Add to dashboard Cite

show abstract

“…100 On the other hand, IBD course may be improved through liver transplantation in patients with PSC in an overlap syndrome. 105 In addition to that, recently, azathioprine has been proposed as an effective first-line therapy for AIH, 106 and this should be kept in mind by clinicians when managing patients with both IBD and AIH.…”

Section: Therapeutic Advances In Gastroenterologymentioning

confidence: 99%

“…100 On the other hand, IBD course may be improved through liver transplantation in patients with PSC in an overlap syndrome. 105 …”

Section: Introductionmentioning

confidence: 99%

“… 114 , 119 – 121 On the contrary, IBD appears to be present at 17% 122 and in around 30% of AIP patients, especially with AIP-2. 105 The association of AIP with UC has been reported to be stronger than with CD. 117 , 119 A French multicenter study found that IBD patients with AIP have higher rates of colectomy than IBD patients without AIP.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Inflammatory bowel disease and immune-mediated inflammatory diseases: looking at the less frequent associations

Bezzio¹,

Corte²,

Vernero

et al. 2022

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Patients with inflammatory bowel disease (IBD) often have other immune-mediated inflammatory diseases (IMIDs), and the prevalence of any IMID is higher in IBD patients than in the general population. IBD and other IMIDs involve alterations in innate and adaptive immune responses. Their co-occurrence depends on shared immune and inflammatory processes, pathogenic mechanisms, and genetic and environmental risk factors, including drugs, especially tumor necrosis factor inhibitors. The more common IMIDs associated with IBD have been widely described, so this review focuses on the less frequent associations. The IMIDs discussed here are skin disorders (psoriasis, atopic dermatitis, vitiligo, epidermolysis bullosa acquisita, cutaneous polyarteritis nodosa, and hidradenitis suppurativa), hepato-pancreatic diseases (autoimmune hepatitis, granulomatous hepatitis, and autoimmune pancreatitis), endocrine diseases (autoimmune thyroid diseases, and type 1 diabetes mellitus), multiple sclerosis, and respiratory diseases (asthma, bronchiectasis, and interstitial pneumonia). The early detection of IMIDs in IBD patients is important to prevent their deleterious clinical course and limit their psychological impact. Care for IBD patients with IMIDs should be multispecialist, with a single therapeutic strategy instead of treating each disease separately.

show abstract

Post-Transplant Management and Complications of Autoimmune Hepatitis, Primary Biliary Cholangitis, and Primary Sclerosing Cholangitis including Disease Recurrence

Henson,

King

2024

Clinics in Liver Disease

View full text Add to dashboard Cite

Inflammatory bowel disease course in liver transplant versus non-liver transplant patients for primary sclerosing cholangitis: LIVIBD, an IG-IBD study

Cited by 6 publications

References 22 publications

Diagnosis and Outcome of Extranodal Primary Intestinal Lymphoma in Inflammatory Bowel Disease: An ECCO CONFER Case Series

Diagnosis and Outcome of Extranodal Primary Intestinal Lymphoma in Inflammatory Bowel Disease: An ECCO CONFER Case Series

Inflammatory bowel disease and immune-mediated inflammatory diseases: looking at the less frequent associations

Post-Transplant Management and Complications of Autoimmune Hepatitis, Primary Biliary Cholangitis, and Primary Sclerosing Cholangitis including Disease Recurrence

Contact Info

Product

Resources

About